Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Viemed Third Quarter 2020 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded. I would now turn the conference over to your host, Todd Zehnder, Chief Operating Officer for Viemed. Thank you. Your may begin.

Thank you, David. Good everyone. Please note that our remarks in this conference call may include forward-looking statements under the U.S. Federal Securities Laws or forward-looking information under applicable Canadian Securities Legislation, which we collectively refer to as forward-looking statements. Such statements reflect the company's current views and intentions with respect to future results or events and are subject to certain risks and uncertainties, which could cause actual results or events to vary from those indicated in our forward-looking statements. Examples of such risks and uncertainties are discussed in our disclosure documents filed with the SEC or the securities regulatory authorities in certain provinces of Canada. Because of these risks and uncertainties, investors should not place undue reliance on forward-looking statements. The forward-looking statements made in this conference call are made as of this date, and the company undertakes no obligation to update or revise any forward-looking statements except as required by law. The third quarter financial results and news release, including the related financial statements is available on the SEC's website. I will now turn it over to Casey to get things started.

Good morning, everyone. Thank you for participating on our call today. Before we get started, I'd like to commend Viemed's greatest asset, our over 500 healthcare professionals who I have the great privilege of leading day-to-day. These associates continue to show bravery, compassion and determination to help others in need during this public health emergency. They continue to place others ahead of themselves and have truly given a better quality of life for our patients within the communities we serve. Thank you for your sincere commitment to our Viemed mission. I will begin with covering some of the key updates on projects that are contributing to setting another record breaking quarter. Additionally, we will discuss how we have built up an all-time high cash balance and our current plans for reinvesting for the future. I will also remark about the recent regulatory outlook which has become considerably more favorable for the HME industry. Since the pandemic began, our team has been resilient in figuring out ways to stay in front of our patients and referral sources. Our efforts of communicating to physicians and patients through our technology platforms have certainly paid off. The third quarter demonstrates the bounce back on referrals similar to pre-COVID numbers inside of our core business. We were also able to add five new territories in the third quarter which brings our year-to-date total to 27 new areas across five new states in 2020. Today, we are conducting business in 36 states and have many good expansion prospects in the fourth quarter. We also took the time in the third quarter to reorganize and restructure our management. We added four new clinical trainers for our sales people. The new structure will allow for further strong field support for all new and existing reps. Our reps have…

All right. Thanks, Casey. In reviewing the financial results, all figures are in U.S. dollars and the full results have been made available on the SEC website, as well as SEDAR. Our core business generated net revenue of $24.9 million during the third quarter of 2020, as compared to net revenues of $20.4 million in the third quarter of 2019, which equates to a 22% increase. Additionally, revenue attributable to our core business was up approximately 8% sequentially, which is a good sign that our business is returning to growth levels achieved before the ongoing COVID pandemic. Additionally, during the current quarter, we generated approximately $8.6 million of equipment and service revenue from the ongoing COVID-19 pandemic. The COVID related revenue resulted primarily from the sales of equipment, contact tracing services and sales of PP&E, as Casey pointed out, it truly helped with various states and communities dealing successfully with the pandemic. Our vent patient count increased slightly from the second quarter and was up about 5% over the prior year third quarter amount. As we discussed last quarter, we retrieved noncompliant vents more aggressively during the current year, as we were seeing the need for equipment at such a high level. As a result of this effort, our average realization per active patient has increased, as we have had less write-offs and bad debts on our patients that we are servicing. While our new patient additions remained somewhat lower than historical figures, the last 60 days have shown better indications of growth, primarily due to better access and our ability to on-board new sales reps after the height of the pandemic. Our margin percentages, both gross and EBITDA, continue to fluctuate as COVID-related product sales during the current year skew comparability. We once again posted very strong margins during…

Thank you, Todd. Another major takeaway from the third quarter is that our cash is now at an all time high. As our company looks to finish 2020 as a strongest year-to-date, our thoughts now turn to the investment strategies that must be made to drive future growth. In addition to the organic growth from our clinically proven industry leading sales force, our focus is shifting to what we can -- what can we acquire that will speed up our initiatives. With remote patient monitoring being a new revenue stream for physicians in 2020, we think there is a unique opportunity to drive our core business through offering a fair market value RPM, revenue solution to our position network. With current strategies in place to bolt-on remote patient monitoring, on-site technology platforms, our team has spent significant time researching our build versus buy versus JV technology options. While we have traditionally not been an acquisitive company, we recognize that an opportunity exists for prudent acquisitions to help expedite our market share growth in the future. In closing, our clinical protocols and ability to test ourselves during this pandemic has made a stronger than ever as a company. The patient centric model that we have created is our competitive differentiator in the marketplace. Our team has never been more unified and committed to taking our company to the next level. The culture we have created at Viemed is second to none, and it has become one that is welcomes challenges and quickly adapt to convert them into opportunities. As a result of our employees working in a growing industry with patients who need us, it makes the Viemed value proposition a very compelling story. Thank you for all of you on the call who have trusted us with your investment and we look forward to continuing to drive further shareholder value. This concludes our prepared remarks. We will now open up the floor for questions.

Thank you. [Operator Instructions] Our first question is from Brooks O'Neil with Lake Street Capital Markets.

Good morning, guys. Hope all is well down there?

All is well, Brooks. Good morning.

Good. So I have a couple of questions, I just try to limit myself a little bit here. But first I am curious, as you look across the business in the things you are working on, what do you see is the most significant constraints on growth and moving forward?

Well, presently it's still access to the hospitals. I mean, we are fortunate to be seeing an uptick in referrals, but we still can't get into about 50% of our facilities right now. So that's currently, I mean, as you look down the road, the number one priority and focus is always growing the vent business, Brooks. And that's beefing up recruiting, that's advancing our training programs and protocols and hiring more people. And so it's no different than it has been in the past just getting our hands on the right people and getting them trained to walk and talk the Viemed way.

Great. Are you seeing any shortage of respiratory therapists out there to hire into the sales side of the business?

No. We are not. I mean, we don’t -- we are not having a shortage of respiratory therapists. What it is, it's really finding the respiratory therapists that we can train to sell and have them be successful in the field. As a refresher, I mean these are clinicians that with the school to take care of people, they didn't go to school to learn sales and so we have to train them to advance their careers and touch more people through communicating and educating physicians about the Viemed offering. And that just can be a challenge sometimes to get that correct person.

Sure. Makes sense. Have you guys think about the -- particularly the gross margin going forward? Obviously, there's been some volatility as Todd said related to the vent sales and equipment sales in PP&E. And I am thinking a little bit more about what impact do you see the growth of the oxygen business having on your margins over the next 12 months to 24 months?

Yeah. I mean, we have always said the vent business has the higher gross margins on a percentage basis but all these ancillary products are just really good offerings. So while it's been very volatile as you mix in the COVID numbers this year. Looking forward we would expect the percentage as we are creeping up on about 20% of our revenue coming from ancillary products, the gross margin percentages will likely come down some. But the most important thing is that notional gross margin is going to be growing at a faster rate, if we didn't have these ancillary products. So if it soften up a little bit, but the most important thing is that's accretive to the bottomline, very accretive to the bottomline. So we are pushing to grow that business significantly.

Makes total sense to me. Let me ask one more and then I will jump back. Obviously in your prepared remarks a little bit more focus on acquisitions this quarter and you highlight the shelf offering. I mean do you think are you trying to say to us, we should expect to see an acquisition here over the next 12 months or something?

I think so, Brooks. We are putting the focus on starting to do our homework on various opportunities, not just other medical equipment businesses in our space that are in areas that were not in with contracts that we don't have, but also strategic acquisitions that might be a good fit for our technology initiatives that are underway. So, the one thing about the pandemic that was great. It helped us grow our cash balance and we are sitting pretty now, it's time to put that cash to work and so we are actively looking at becoming more acquisitive.

Great. Makes sense. Keep up all the good work guys. Thanks a lot.

Thanks, Brooks.

Thanks.

Our next question is from Anton Hie with RBC Capital Markets.

Thanks. Hi, guys. How would you characterize the overall sort of organic growth in the quarter and specifically kind of from month-to-month, if you could kind of shed a little light on that and maybe what you saw in October relative to kind of where you closed out third quarter?

Yeah. I mean, well, this quarter was back to what we always expected, which is more on an annualized rate of being a 30% to 40% growth. It wasn't like it was all over the Board, it's just been consistently better in the third quarter than it was in the second and so that's a good sign. It didn't just come roaring back in September. It's been a progressive improvement as the pandemic has I guess been elongated. It is not like it's over. We recognize that. We still have challenges. But it was just a good solid growth quarter. As it relates to October, we have the guidance out there. It was once again a good quarter for, I mean, a good month for referrals and so forth. So it’s -- that's included in what we have put out there for the fourth quarter and it's continuing that ongoing trend of better numbers month over month.

Okay. Great. And then a couple of that kind of feed off of what the Brooks’ line of questioning there, just on the hiring process, especially for RTs, and I guess, for inside reps too. Has there been kind of any change in that process that you have had to adjust maybe as the pandemic has kind of continued on here and has that affected your ability to go into any certain markets, maybe where there is already increased activity from a COVID standpoint?

Yeah. From a COVID standpoint, the biggest change, we really just getting folks in and trained and up and running, getting back out into the field, walking shoulder to shoulder with our clinical trainers that was a bit of a challenge in Q2 and trickled into Q3 as well. As confidence rises just amongst Americans during this pandemic on how to just continue to live, so does access to facilities and patients getting out and really treating their COPD more than they were before. So that's exciting for us. I mean what we have done along the way is, we have beefed up our recruiting efforts. We have changed some things around. We are always trying new things in terms of recruiting working with different types of firms and challenging our folks that are boots on the ground, they really work the hallways of the hospitals and facilities and educate more RFPs out there that the opportunity to work with Viemed is out and about. And so we have beefed up some of our recruiting efforts internally with our own people and how they are rewarded for finding new recruits. So we are always making changes in that regard. I mean that's our number one priority is just to get good people into this organization, because once we get them into another area, that's another 60-mile region that we can get business from. So that's our current expansion strategy.

Okay. And then on the ancillaries, is that -- do you have sort of a penetration rate, if you will, that you want to, do you want to get to, whether that's a sales mix or kind of a sell-through into existing markets rate or something like that, that you are targeting or is that just sort of, you take it as it comes and it's nice because it adds operating leverage?

We don't have a specific target per say, but we do know that the best thing for referral sources and for patients is to offer a wide array of services and it's best for operating leverage as you say. So while we don't have a defined goal of the product mix, the way we do look at it, it's not through penetration in exact market, it's the contribution of these ancillary products to the business. We don't hang our heads if that number doesn't grow materially in a quarter, because of our vent growth. So, our overall, I guess, strategy and vision is to continue to grow that product mix. I think it was 18% in the third quarter. We would love to have that in the 20%s next year, but the number one goal is to have the overall business growing at that material level that we have always exhibited.

Okay. Great. Thanks, guys.

Thanks, Anton.

Our next question is from Nick Corcoran with Acumen Capital.

Good morning. Just a couple of questions from me, the first is on the revenue per patient, quite high in the quarter. How much room do you see that having to grow going forward and how stable is that?

Well, I think, if you look at it just on a bit basis, we are pretty much where we think we will be. Although, maybe our average realization could come up a little bit as the overall bad debt may stabilize at a low level. When you look at it, since we have picked up noncompliant patients and so forth will always have patients that admit to facilities and things like that. So I don't think it will have a material move from here, but you clearly see the impact of what we have been doing during the current year from having been on the right patients to also having an optimized workflow has come through. If you are including ancillary products in the average realization per patient, which as we continue to grow that business might not be the way to look at it, if it becomes more material, going back to Anton's question on the last one, it should continue to grow, because we should have more ancillary product revenue coming through it.

Great. And can you give any more color on the contract tracing contract, whether size, duration or anything on along those lines has changed since the last call?

Yeah. So nothing has changed. We have been executing on that contract, really kind of the beginning of September late August, early September. It's a one year contract is what we signed for. That doesn't necessarily mean it will be out there for the entire year. But that's what it's for and it's looking very good. And as we mentioned last quarter and which is included in our current guidance, it's a little bit over about $1 million per month of cost – of revenue. So it should go through mid-next summer or through next August.

Great. That's all from me. Thank you.

Thanks, Nick.

[Operator Instructions] Our next question is from Prasath Pandurangan with Bloom Burton.

Hi. Thanks for taking my questions. Firstly, could you give a little more color on the oxygen concentrator business, including the main drivers and the revenue potential? And how correlated are these revenues with the number of vent patients?

Yeah. So, the oxygen business, we have different stages COPD. Stage I being in the bottom of less severe and Stage IV being the most severe. At Stage I, they would typically become candidates for oxygen therapy. So think of your less sick patients as the ones that will need an oxygen concentrator. The way that we have always been in oxygen business here locally in Louisiana and we decided last August to release that offering nationally to our sales reps and the reason for it was because this is a driver of the business and it's a nice complement to it. We see that about 20% of our referrals come from our oxygen referrals. So that was the reason for us getting into it. And then along the way, we had relaxed rules on competitive bidding for O2, which allowed us to sell into the metropolitan market. We got an increased reimbursement for the rural areas to provide O2. So it's just become a nice piece of business and it's one that's growing at a fast rate. Now, we add the assistance that we are providing the energy call center with convert with some of our private insurance contracts, that's another channel of getting more oxygen business and then ultimately more vent business, so it's just been a really good piece of ancillary business for us.

And then the SG&A expenses were lower than last quarter, I am trying to understand the differences are mainly due to the differences in the Fantom share plant, and if yes, what would be the normalized quarterly number for 4Q in 2021?

Well, we don't guide SG&A going forward, but I think this quarter is a pretty fair run rate. We obviously are continuing to hire more people. But last quarter as we talked about was very high because of the stock price volatility. So, I feel like this is more of a steady-state number going forward, but it's not formally guided just now.

And then again, you don't guide the number of vent patients, but broadly where do you see the number of vent patients being at the end of this year and then going forward into 2021?

We want to get back to those historical growth rate. We don't focus just necessarily on vent patient per se. It's always been a good operational statistics to talk about. But we want to get back to servicing more patients. We guide revenue only but you should expect us to continue vent patients as we have historically.

Got it. Thank you. That's correct.

Thanks.

Ladies and gentlemen, we have reached the end of the question-and-answer session and I would like to turn the call back to management for closing remarks.

Okay. We want to thank everybody for their time this morning and look forward to following up with anyone down the road.

Thank you. This concludes today's conference. You may disconnect your lines at this time.